Cancer dependencies missed by some CRISPR guides
Scientists discovered that, depending on germline variation, CRISPR-based experiments can result in false negatives.
List view / Grid view
Scientists discovered that, depending on germline variation, CRISPR-based experiments can result in false negatives.
As the industry looks beyond CRISPR to safely introduce therapeutic genomic changes anywhere in the body, in vivo gene editing holds immense potential to address diseases with a genetic basis. Boston-based biotech Tessera Therapeutics is pioneering the next generation of genetic medicines with its Gene Writing™ platform. At this year’s…
HIV-Tocky, a new viral reporter system, uncovers the molecular mechanisms of provirus silencing and expression.
The novel drug, ETD001, could provide an improved approach for mucus clearance in cystic fibrosis patients.
The algorithm can accurately diagnose cases of lung adenocarcinoma, determining structural features that are statistically most significant for assessing disease severity and likelihood of tumour recurrence.
Researchers have developed a new in vitro co-culture system which enables an in-depth molecular analysis of atherosclerosis.
Intestinal epithelial organoids highlight a pathway implicated in CD, named major histocompatibility complex (MHC)-I.
A new study reveals that pain management could be greatly improved by considering patient sex as fundamental.
Researchers found, using human respiratory epithelium organoids, that P. aeruginosa breaches respiratory epithelia by goblet cell invasion.
The development of a new membrane which better mimics human extracellular membranes will enable more accurate disease research.
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
Researchers have identified a new biological pathway driving IBD and similar conditions that could be targeted with MEK inhibitors.
A human pancreatic cancer fibrotic barrier model illuminates how targeting the TGFβ/ROCK2/YAP signalling axis could enhance drug delivery.
The future of liquid biopsy is poised to revolutionise medical diagnostics and treatment. Explore the latest advancements and future prospects of liquid biopsy in our comprehensive eBook.
As antimicrobial resistance continues to advance, novel therapeutics are needed that stop infection and do not contribute to resistance. Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections. Recce’s lead candidate, RECCE® 327 (R327), is a…